The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug before it could work—forcing millions of patients to rely on daily injections.
“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University ...
CNW/ -- (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...
A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...
The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes. The Food and Drug ...
Those with type 1, and many with type 2, will need insulin a few times a day, and that’s usually delivered through a subcutaneous injection. Not only is that uncomfortable, but it can be hard for ...
Regular insulin, which is often used in pregnancy for the treatment of diabetes, has some drawbacks: it starts its action from 30 to 60 min after subcutaneous injection and it peaks too late (2-3 h ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results